Seeking Alpha
2023-04-11 16:02:39

Hot Stocks: TLRY drops on earnings; MARA, MSTR, RIOT, COIN boosted by crypto rise; PSMT gains; MRNA falls

The major market averages are neutral during Tuesday's intraday trading as investors wait for this week's important inflation data release, which will indicate how quickly interest rates will rise in the future. In terms of specific stocks, Pricesmart ( NASDAQ: PSMT ) advanced on strong results news while Tilray ( NASDAQ: TLRY ) declined on Q3 sales disappointment. Elsewhere, Coinbase ( NASDAQ: COIN ), Marathon Digital ( NASDAQ: MARA ), MicroStrategy ( NASDAQ: MSTR ) and RIOT ( NASDAQ: RIOT ) led a rally in crypto-focused stocks as the Bitcoin ( BTC-USD ) crossed the $30K threshold. Meanwhile, TG Therapeutics ( NASDAQ: TGTX ) rose to a 52-week high on B. Riley's comments, while Moderna ( NASDAQ: MRNA ) fell as its flu vaccine mRNA-1010 failed to satisfy an early success benchmark. Gainers PriceSmart ( PSMT ) rose more than 10% after beating the expected mark in Q2 with a sales increase of around 10%. Shares of TG Therapeutics ( TGTX ) rose 17% to a new 52-week high after B. Riley Securities reported an increasing trend in demand for the company's recently authorised multiple sclerosis medication Briumvi. Meanwhile, crypto-linked stocks Coinbase ( COIN ) +7.4% , Marathon Digital ( MARA ) +9% , Riot Platforms ( RIOT ) +12.7% , MicroStrategy ( MSTR ) +6.3% , Hive Blockchain ( NASDAQ: HIVE ) +5.4% , and CleanSpark ( NASDAQ: CLSK ) +10.9% led the recovery in the crypto market, with Bitcoin ( BTC-USD ) surpassing the $30K threshold , maintaining the highest levels seen since June last year, when it last surpassed $30,000. Decliners Tilray ( TLRY ) slumped roughly 8% after announcing lower-than-expected revenue for the third quarter, driven by a 14% year-on-year fall in net cannabis sales to $47.5 million. In addition, the company recorded a gross loss of $11.7 million, compared to a profit of $40 million the previous year. In the meantime, Moderna ( MRNA ) fell more than 5% after its seasonal influenza (flu) vaccine mRNA-1010 failed to accumulate enough cases at an interim effectiveness analysis to announce early success in a Northern Hemisphere phase 3 study. To keep track of Wall Street's biggest winners and losers throughout the session, head over to Seeking Alpha's On The Move section .

获取加密通讯
阅读免责声明 : 此处提供的所有内容我们的网站,超链接网站,相关应用程序,论坛,博客,社交媒体帐户和其他平台(“网站”)仅供您提供一般信息,从第三方采购。 我们不对与我们的内容有任何形式的保证,包括但不限于准确性和更新性。 我们提供的内容中没有任何内容构成财务建议,法律建议或任何其他形式的建议,以满足您对任何目的的特定依赖。 任何使用或依赖我们的内容完全由您自行承担风险和自由裁量权。 在依赖它们之前,您应该进行自己的研究,审查,分析和验证我们的内容。 交易是一项高风险的活动,可能导致重大损失,因此请在做出任何决定之前咨询您的财务顾问。 我们网站上的任何内容均不构成招揽或要约